| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| 4503.T - Astellas Pharma Inc. | BUY | 6,000 @ JPY 12.6669 | JPY 76,001 | The ETF bought 6000 new shares of 4503.T (Astellas Pharma Inc.). The shares were bought for an average price of 12.6669 compared to the previous average buy price of 10.7471. This is 17.9% higher than average price of previous purchases of 4503.T. |
| 4568.T - Daiichi Sankyo Company, Limited | BUY | 2,700 @ JPY 24.5397 | JPY 66,257 | The ETF bought 2700 new shares of 4568.T (Daiichi Sankyo Company, Limited). The shares were bought for an average price of 24.5397 compared to the previous average buy price of 24.0521. This is 2.0% higher than average price of previous purchases of 4568.T. |
| 4519.T - Chugai Pharmaceutical Co., Ltd. | BUY | 900 @ JPY 53.5237 | JPY 48,171 | The ETF bought 900 new shares of 4519.T (Chugai Pharmaceutical Co., Ltd.). The shares were bought for an average price of 53.5237 compared to the previous average buy price of 46.3112. This is 15.6% higher than average price of previous purchases of 4519.T. |
| 4523.T - Eisai Co., Ltd. | BUY | 1,200 @ JPY 32.1668 | JPY 38,600 | The ETF bought 1200 new shares of 4523.T (Eisai Co., Ltd.). The shares were bought for an average price of 32.1668 compared to the previous average buy price of 30.2753. This is 6.2% higher than average price of previous purchases of 4523.T. |
| 6869.T - Sysmex Corporation | BUY | 2,300 @ JPY 10.0285 | JPY 23,066 | The ETF bought 2300 new shares of 6869.T (Sysmex Corporation). The shares were bought for an average price of 10.0285 compared to the previous average buy price of 12.6105. This is -20.5% lower than average price of previous purchases of 6869.T. |
| 4151.T - Kyowa Kirin Co., Ltd. | BUY | 1,100 @ JPY 16.9127 | JPY 18,604 | The ETF bought 1100 new shares of 4151.T (Kyowa Kirin Co., Ltd.). The shares were bought for an average price of 16.9127 compared to the previous average buy price of 15.6107. This is 8.3% higher than average price of previous purchases of 4151.T. |
| 7741.T - HOYA Corporation | BUY | 100 @ JPY 148.346 | JPY 14,835 | The ETF bought 100 new shares of 7741.T (HOYA Corporation). The shares were bought for an average price of 148.346 compared to the previous average buy price of 145.171. This is 2.2% higher than average price of previous purchases of 7741.T. |
| 4502.T - Takeda Pharmaceutical Company Limited | BUY | 400 @ JPY 28.5486 | JPY 11,419 | The ETF bought 400 new shares of 4502.T (Takeda Pharmaceutical Company Limited). The shares were bought for an average price of 28.5486 compared to the previous average buy price of 28.7904. This is -0.8% lower than average price of previous purchases of 4502.T. |
| 4578.T - Otsuka Holdings Co., Ltd. | BUY | 100 @ JPY 55.4577 | JPY 5,546 | The ETF bought 100 new shares of 4578.T (Otsuka Holdings Co., Ltd.). The shares were bought for an average price of 55.4577 compared to the previous average buy price of 53.253. This is 4.1% higher than average price of previous purchases of 4578.T. |
| 2413.T - M3, Inc. | BUY | 300 @ JPY 16.5381 | JPY 4,961 | The ETF bought 300 new shares of 2413.T (M3, Inc.). The shares were bought for an average price of 16.5381 compared to the previous average buy price of 14.2936. This is 15.7% higher than average price of previous purchases of 2413.T. |
| 4543.T - Terumo Corporation | BUY | 300 @ JPY 15.5679 | JPY 4,670 | The ETF bought 300 new shares of 4543.T (Terumo Corporation). The shares were bought for an average price of 15.5679 compared to the previous average buy price of 16.6368. This is -6.4% lower than average price of previous purchases of 4543.T. |
| 7733.T - Olympus Corporation | BUY | 300 @ JPY 13.3873 | JPY 4,016 | The ETF bought 300 new shares of 7733.T (Olympus Corporation). The shares were bought for an average price of 13.3873 compared to the previous average buy price of 12.5576. This is 6.6% higher than average price of previous purchases of 7733.T. |
| 4507.T - Shionogi & Co., Ltd. | BUY | 200 @ JPY 17.5019 | JPY 3,500 | The ETF bought 200 new shares of 4507.T (Shionogi & Co., Ltd.). The shares were bought for an average price of 17.5019 compared to the previous average buy price of 16.8555. This is 3.8% higher than average price of previous purchases of 4507.T. |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 157.2 | USD 0 | The current share valuation price of A based on adjusted close was USD 157.2. The average price that A shares were previous bought at was USD 134.498. The current market price is 16.9% higher than average price they were purchased at. The value of the holding in A has increased by USD 197,139 compared to the previous valuation of Agilent Technologies Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 231.8 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 231.8. The average price that ABBV shares were previous bought at was USD 206.46. The current market price is 12.3% higher than average price they were purchased at. The value of the holding in ABBV has increased by USD 330,143 compared to the previous valuation of AbbVie Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 128.05 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 128.05. The average price that ABT shares were previous bought at was USD 131.614. The current market price is -2.7% lower than average price they were purchased at. The value of the holding in ABT has increased by USD 74,711 compared to the previous valuation of Abbott Laboratories however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| ALC.SW - | HOLD | 0 @ CHF 78.6532 | CHF 0 | The current share valuation price of ALC.SW based on adjusted close was CHF 78.6532. The average price that ALC.SW shares were previous bought at was CHF 77.7293. The current market price is 1.2% higher than average price they were purchased at. The value of the holding in ALC.SW has increased by CHF 292,563 compared to the previous valuation of however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 429.8 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 429.8. The average price that ALNY shares were previous bought at was USD 420.306. The current market price is 2.3% higher than average price they were purchased at. The value of the holding in ALNY has fallen by USD 46,086 compared to the previous valuation of Alnylam Pharmaceuticals Inc |
| AMGN - Amgen Inc | HOLD | 0 @ USD 341.11 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 341.11. The average price that AMGN shares were previous bought at was USD 302.352. The current market price is 12.8% higher than average price they were purchased at. The value of the holding in AMGN has increased by USD 244,956 compared to the previous valuation of Amgen Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| ARGX.BR - Argenx SE | HOLD | 0 @ EUR 907.656 | EUR 0 | The current share valuation price of ARGX.BR based on adjusted close was EUR 907.656. The average price that ARGX.BR shares were previous bought at was EUR 847.148. The current market price is 7.1% higher than average price they were purchased at. The value of the holding in ARGX.BR has increased by EUR 8,567 compared to the previous valuation of Argenx SE however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| AZN.L - AstraZeneca PLC | HOLD | 0 @ GBP 185.789 | GBP 0 | The current share valuation price of AZN.L based on adjusted close was GBP 185.789. The average price that AZN.L shares were previous bought at was GBP 159.117. The current market price is 16.8% higher than average price they were purchased at. The value of the holding in AZN.L has increased by GBP 468,332 compared to the previous valuation of AstraZeneca PLC however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| BAX - Baxter International Inc | HOLD | 0 @ USD 18.66 | USD 0 | The current share valuation price of BAX based on adjusted close was USD 18.66. The average price that BAX shares were previous bought at was USD 19.5935. The current market price is -4.8% lower than average price they were purchased at. The value of the holding in BAX has increased by USD 7,259 compared to the previous valuation of Baxter International Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| BAYN.DE - Bayer AG | HOLD | 0 @ EUR 35.6472 | EUR 0 | The current share valuation price of BAYN.DE based on adjusted close was EUR 35.6472. The average price that BAYN.DE shares were previous bought at was EUR 31.4423. The current market price is 13.4% higher than average price they were purchased at. The value of the holding in BAYN.DE has increased by EUR 7,296 compared to the previous valuation of Bayer AG however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| BDX - Becton Dickinson and Company | HOLD | 0 @ USD 195.49 | USD 0 | The current share valuation price of BDX based on adjusted close was USD 195.49. The average price that BDX shares were previous bought at was USD 183.347. The current market price is 6.6% higher than average price they were purchased at. The value of the holding in BDX has increased by USD 27,715 compared to the previous valuation of Becton Dickinson and Company however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 181.96 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 181.96. The average price that BIIB shares were previous bought at was USD 173.846. The current market price is 4.7% higher than average price they were purchased at. The value of the holding in BIIB has increased by USD 45,849 compared to the previous valuation of Biogen Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 126.725 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 126.725. The average price that BIM.PA shares were previous bought at was EUR 127.24. The current market price is -0.4% lower than average price they were purchased at. The value of the holding in BIM.PA has increased by EUR 3,146 compared to the previous valuation of BioMerieux however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 49.05 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 49.05. The average price that BMY shares were previous bought at was USD 47.3663. The current market price is 3.6% higher than average price they were purchased at. The value of the holding in BMY has increased by USD 158,864 compared to the previous valuation of Bloomsbury Publishing Plc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 101.36 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 101.36. The average price that BSX shares were previous bought at was USD 101.156. The current market price is 0.2% higher than average price they were purchased at. The value of the holding in BSX has increased by USD 109,743 compared to the previous valuation of Boston Scientific Corporation however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 101.36 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 101.36. The average price that BSX shares were previous bought at was USD 101.156. The current market price is 0.2% higher than average price they were purchased at. The value of the holding in BSX has increased by USD 109,743 compared to the previous valuation of MULSTRXSSXIMETFP however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| CAH - Cardinal Health Inc | HOLD | 0 @ USD 213.73 | USD 0 | The current share valuation price of CAH based on adjusted close was USD 213.73. The average price that CAH shares were previous bought at was USD 167.417. The current market price is 27.7% higher than average price they were purchased at. The value of the holding in CAH has increased by USD 122,746 compared to the previous valuation of Cardinal Health Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| CI - Cigna Corp | HOLD | 0 @ USD 278.2 | USD 0 | The current share valuation price of CI based on adjusted close was USD 278.2. The average price that CI shares were previous bought at was USD 291.006. The current market price is -4.4% lower than average price they were purchased at. The value of the holding in CI has increased by USD 242,139 compared to the previous valuation of Cigna Corp however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| CNC - Concurrent Technologies Plc | HOLD | 0 @ USD 39.66 | USD 0 | The current share valuation price of CNC based on adjusted close was USD 39.66. The average price that CNC shares were previous bought at was USD 38.4416. The current market price is 3.2% higher than average price they were purchased at. The value of the holding in CNC has increased by USD 136,865 compared to the previous valuation of Concurrent Technologies Plc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| COH.AX - | HOLD | 0 @ AUD 177.924 | AUD 0 | The current share valuation price of COH.AX based on adjusted close was AUD 177.924. The average price that COH.AX shares were previous bought at was AUD 185.819. The current market price is -4.2% lower than average price they were purchased at. The value of the holding in COH.AX has increased by AUD 37,334 compared to the previous valuation of however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| COLO-B.CO - | HOLD | 0 @ DKK 90.9021 | DKK 0 | The current share valuation price of COLO-B.CO based on adjusted close was DKK 90.9021. The average price that COLO-B.CO shares were previous bought at was DKK 92.2349. The current market price is -1.4% lower than average price they were purchased at. The value of the holding in COLO-B.CO has increased by DKK 76,932 compared to the previous valuation of however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| COO - The Cooper Companies, Inc. Common Stock | HOLD | 0 @ USD 78.21 | USD 0 | The current share valuation price of COO based on adjusted close was USD 78.21. The average price that COO shares were previous bought at was USD 75.6989. The current market price is 3.3% higher than average price they were purchased at. The value of the holding in COO has increased by USD 40,711 compared to the previous valuation of The Cooper Companies, Inc. Common Stock however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| COR - Cencora Inc. | HOLD | 0 @ USD 374.75 | USD 0 | The current share valuation price of COR based on adjusted close was USD 374.75. The average price that COR shares were previous bought at was USD 320.421. The current market price is 17.0% higher than average price they were purchased at. The value of the holding in COR has increased by USD 91,826 compared to the previous valuation of Cencora Inc. however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| CSL.AX - | HOLD | 0 @ AUD 117.426 | AUD 0 | The current share valuation price of CSL.AX based on adjusted close was AUD 117.426. The average price that CSL.AX shares were previous bought at was AUD 120.123. The current market price is -2.2% lower than average price they were purchased at. The value of the holding in CSL.AX has fallen by AUD 18,675 compared to the previous valuation of |
| CVS - CVS Health Corp | HOLD | 0 @ USD 78.47 | USD 0 | The current share valuation price of CVS based on adjusted close was USD 78.47. The average price that CVS shares were previous bought at was USD 71.1294. The current market price is 10.3% higher than average price they were purchased at. The value of the holding in CVS has increased by USD 42,301 compared to the previous valuation of CVS Health Corp however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| DEMANT.CO - | HOLD | 0 @ DKK 33.8715 | DKK 0 | The current share valuation price of DEMANT.CO based on adjusted close was DKK 33.8715. The average price that DEMANT.CO shares were previous bought at was DKK 35.87. The current market price is -5.6% lower than average price they were purchased at. The value of the holding in DEMANT.CO has increased by DKK 11,166 compared to the previous valuation of however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| DGX - Quest Diagnostics Incorporated | HOLD | 0 @ USD 192.35 | USD 0 | The current share valuation price of DGX based on adjusted close was USD 192.35. The average price that DGX shares were previous bought at was USD 180.731. The current market price is 6.4% higher than average price they were purchased at. The value of the holding in DGX has increased by USD 3,961 compared to the previous valuation of Quest Diagnostics Incorporated however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 230.77 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 230.77. The average price that DHR shares were previous bought at was USD 209.968. The current market price is 9.9% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 174,245 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 230.77 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 230.77. The average price that DHR shares were previous bought at was USD 209.968. The current market price is 9.9% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 174,245 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| DIM.PA - Sartorius Stedim Biotech | HOLD | 0 @ EUR 234.141 | EUR 0 | The current share valuation price of DIM.PA based on adjusted close was EUR 234.141. The average price that DIM.PA shares were previous bought at was EUR 220.814. The current market price is 6.0% higher than average price they were purchased at. The value of the holding in DIM.PA has increased by EUR 13,502 compared to the previous valuation of Sartorius Stedim Biotech however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| DXCM - DexCom Inc | HOLD | 0 @ USD 61.69 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 61.69. The average price that DXCM shares were previous bought at was USD 69.4664. The current market price is -11.2% lower than average price they were purchased at. The value of the holding in DXCM has fallen by USD 5,967 compared to the previous valuation of DexCom Inc |
| EL.PA - EssilorLuxottica SA | HOLD | 0 @ EUR 356.934 | EUR 0 | The current share valuation price of EL.PA based on adjusted close was EUR 356.934. The average price that EL.PA shares were previous bought at was EUR 342.762. The current market price is 4.1% higher than average price they were purchased at. The value of the holding in EL.PA has increased by EUR 153,286 compared to the previous valuation of EssilorLuxottica SA however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 336.27 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 336.27. The average price that ELV shares were previous bought at was USD 335.766. The current market price is 0.2% higher than average price they were purchased at. The value of the holding in ELV has increased by USD 229,468 compared to the previous valuation of Elevance Health Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 336.27 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 336.27. The average price that ELV shares were previous bought at was USD 335.766. The current market price is 0.2% higher than average price they were purchased at. The value of the holding in ELV has increased by USD 229,468 compared to the previous valuation of Elevance Health Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| ERF.PA - Eurofins Scientific SE | HOLD | 0 @ EUR 68.2418 | EUR 0 | The current share valuation price of ERF.PA based on adjusted close was EUR 68.2418. The average price that ERF.PA shares were previous bought at was EUR 69.3899. The current market price is -1.7% lower than average price they were purchased at. The value of the holding in ERF.PA has increased by EUR 3,298 compared to the previous valuation of Eurofins Scientific SE however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 86.82 | USD 0 | The current share valuation price of EW based on adjusted close was USD 86.82. The average price that EW shares were previous bought at was USD 78.715. The current market price is 10.3% higher than average price they were purchased at. The value of the holding in EW has increased by USD 199,040 compared to the previous valuation of Edwards Lifesciences Corp however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| FME.DE - Fresenius Medical Care AG | HOLD | 0 @ EUR 48.1809 | EUR 0 | The current share valuation price of FME.DE based on adjusted close was EUR 48.1809. The average price that FME.DE shares were previous bought at was EUR 50.9587. The current market price is -5.5% lower than average price they were purchased at. The value of the holding in FME.DE has increased by EUR 2,439 compared to the previous valuation of Fresenius Medical Care AG however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| FPH.NZ - | HOLD | 0 @ NZD 20.5795 | NZD 0 | The current share valuation price of FPH.NZ based on adjusted close was NZD 20.5795. The average price that FPH.NZ shares were previous bought at was NZD 21.1253. The current market price is -2.6% lower than average price they were purchased at. The value of the holding in FPH.NZ has fallen by NZD 4,042 compared to the previous valuation of |
| FRE.DE - Fresenius SE & Co KGaA | HOLD | 0 @ EUR 55.1069 | EUR 0 | The current share valuation price of FRE.DE based on adjusted close was EUR 55.1069. The average price that FRE.DE shares were previous bought at was EUR 52.4017. The current market price is 5.2% higher than average price they were purchased at. The value of the holding in FRE.DE has increased by EUR 6,338 compared to the previous valuation of Fresenius SE & Co KGaA however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| GALD.SW - | HOLD | 0 @ CHF 192.239 | CHF 0 | The current share valuation price of GALD.SW based on adjusted close was CHF 192.239. The average price that GALD.SW shares were previous bought at was CHF 184.4. The current market price is 4.3% higher than average price they were purchased at. The value of the holding in GALD.SW has increased by CHF 61,326 compared to the previous valuation of however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| GEHC - GE HealthCare Technologies Inc. | HOLD | 0 @ USD 79.96 | USD 0 | The current share valuation price of GEHC based on adjusted close was USD 79.96. The average price that GEHC shares were previous bought at was USD 75.4292. The current market price is 6.0% higher than average price they were purchased at. The value of the holding in GEHC has increased by USD 16,426 compared to the previous valuation of GE HealthCare Technologies Inc. however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 127.12 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 127.12. The average price that GILD shares were previous bought at was USD 116.15. The current market price is 9.4% higher than average price they were purchased at. The value of the holding in GILD has increased by USD 267,110 compared to the previous valuation of Guild Esports Plc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| GMAB.CO - | HOLD | 0 @ DKK 309.922 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 309.922. The average price that GMAB.CO shares were previous bought at was DKK 280.97. The current market price is 10.3% higher than average price they were purchased at. The value of the holding in GMAB.CO has increased by DKK 3,030 compared to the previous valuation of however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| GRF.MC - Grifols SA | HOLD | 0 @ EUR 11.9441 | EUR 0 | The current share valuation price of GRF.MC based on adjusted close was EUR 11.9441. The average price that GRF.MC shares were previous bought at was EUR 13.2076. The current market price is -9.6% lower than average price they were purchased at. The value of the holding in GRF.MC has increased by EUR 1,435 compared to the previous valuation of Grifols SA however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 23.6518 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 23.6518. The average price that GSK.L shares were previous bought at was GBP 23.2527. The current market price is 1.7% higher than average price they were purchased at. The value of the holding in GSK.L has increased by GBP 32,251 compared to the previous valuation of GlaxoSmithKline PLC however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| HCA - HCA Holdings Inc | HOLD | 0 @ USD 515.85 | USD 0 | The current share valuation price of HCA based on adjusted close was USD 515.85. The average price that HCA shares were previous bought at was USD 438.288. The current market price is 17.7% higher than average price they were purchased at. The value of the holding in HCA has increased by USD 59,418 compared to the previous valuation of HCA Holdings Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| HIK.L - | HOLD | 0 @ GBP 21.0824 | GBP 0 | The current share valuation price of HIK.L based on adjusted close was GBP 21.0824. The average price that HIK.L shares were previous bought at was GBP 22.9595. The current market price is -8.2% lower than average price they were purchased at. The value of the holding in HIK.L has increased by GBP 117 compared to the previous valuation of however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| HLN.L - Haleon PLC | HOLD | 0 @ GBP 4.9346 | GBP 0 | The current share valuation price of HLN.L based on adjusted close was GBP 4.9346. The average price that HLN.L shares were previous bought at was GBP 4.88935. The current market price is 0.9% higher than average price they were purchased at. The value of the holding in HLN.L has increased by GBP 19,630 compared to the previous valuation of Haleon PLC however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.88 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.88. The average price that HOLX shares were previous bought at was USD 69.7374. The current market price is 7.4% higher than average price they were purchased at. The value of the holding in HOLX has increased by USD 9,223 compared to the previous valuation of Hologic Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| HUM - Hummingbird Resources PLC | HOLD | 0 @ USD 237.88 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 237.88. The average price that HUM shares were previous bought at was USD 267.564. The current market price is -11.1% lower than average price they were purchased at. The value of the holding in HUM has increased by USD 149,730 compared to the previous valuation of Hummingbird Resources PLC however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| HUM - Humana Inc | HOLD | 0 @ USD 237.88 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 237.88. The average price that HUM shares were previous bought at was USD 267.564. The current market price is -11.1% lower than average price they were purchased at. The value of the holding in HUM has increased by USD 149,730 compared to the previous valuation of Humana Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| IDXX - IDEXX Laboratories Inc | HOLD | 0 @ USD 766.68 | USD 0 | The current share valuation price of IDXX based on adjusted close was USD 766.68. The average price that IDXX shares were previous bought at was USD 609.637. The current market price is 25.8% higher than average price they were purchased at. The value of the holding in IDXX has increased by USD 217,475 compared to the previous valuation of IDEXX Laboratories Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| ILMN - Illumina Inc | HOLD | 0 @ USD 129.64 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 129.64. The average price that ILMN shares were previous bought at was USD 102.955. The current market price is 25.9% higher than average price they were purchased at. The value of the holding in ILMN has increased by USD 11,648 compared to the previous valuation of Illumina Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| INCY - Incyte Corporation | HOLD | 0 @ USD 105.55 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 105.55. The average price that INCY shares were previous bought at was USD 103.737. The current market price is 1.7% higher than average price they were purchased at. The value of the holding in INCY has fallen by USD 8,396 compared to the previous valuation of Incyte Corporation |
| INSM - Insmed Inc | HOLD | 0 @ USD 209.02 | USD 0 | |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 148.115 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 148.115. The average price that IPN.PA shares were previous bought at was EUR 135.691. The current market price is 9.2% higher than average price they were purchased at. The value of the holding in IPN.PA has increased by EUR 2,077 compared to the previous valuation of Ipsen SA however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 231.92 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 231.92. The average price that IQV shares were previous bought at was USD 195.252. The current market price is 18.8% higher than average price they were purchased at. The value of the holding in IQV has increased by USD 153,003 compared to the previous valuation of IQVIA Holdings Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 578.87 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 578.87. The average price that ISRG shares were previous bought at was USD 538.222. The current market price is 7.6% higher than average price they were purchased at. The value of the holding in ISRG has increased by USD 251,594 compared to the previous valuation of Intuitive Surgical Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 206.67 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 206.67. The average price that JNJ shares were previous bought at was USD 169.389. The current market price is 22.0% higher than average price they were purchased at. The value of the holding in JNJ has increased by USD 92,957 compared to the previous valuation of Johnson & Johnson however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| LH - Laboratory Corporation of America Holdings | HOLD | 0 @ USD 269.83 | USD 0 | The current share valuation price of LH based on adjusted close was USD 269.83. The average price that LH shares were previous bought at was USD 262.51. The current market price is 2.8% higher than average price they were purchased at. The value of the holding in LH has increased by USD 7,734 compared to the previous valuation of Laboratory Corporation of America Holdings however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| LLY - Eli Lilly and Company | HOLD | 0 @ USD 1109.94 | USD 0 | The current share valuation price of LLY based on adjusted close was USD 1109.94. The average price that LLY shares were previous bought at was USD 835.036. The current market price is 32.9% higher than average price they were purchased at. The value of the holding in LLY has increased by USD 2,593,855 compared to the previous valuation of Eli Lilly and Company however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| LONN.SW - | HOLD | 0 @ CHF 666.956 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 666.956. The average price that LONN.SW shares were previous bought at was CHF 676.753. The current market price is -1.4% lower than average price they were purchased at. The value of the holding in LONN.SW has increased by CHF 7,175 compared to the previous valuation of however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| MCK - McKesson Corporation | HOLD | 0 @ USD 889.28 | USD 0 | The current share valuation price of MCK based on adjusted close was USD 889.28. The average price that MCK shares were previous bought at was USD 778.024. The current market price is 14.3% higher than average price they were purchased at. The value of the holding in MCK has increased by USD 293,793 compared to the previous valuation of McKesson Corporation however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| MDT - Medtronic PLC | HOLD | 0 @ USD 105.35 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 105.35. The average price that MDT shares were previous bought at was USD 97.2856. The current market price is 8.3% higher than average price they were purchased at. The value of the holding in MDT has increased by USD 72,169 compared to the previous valuation of Medtronic PLC however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 105.66 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 105.66. The average price that MRK shares were previous bought at was USD 84.0604. The current market price is 25.7% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 909,622 compared to the previous valuation of Marks Electrical Group PLC however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 105.66 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 105.66. The average price that MRK shares were previous bought at was USD 84.0604. The current market price is 25.7% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 909,622 compared to the previous valuation of Merck & Company Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| MRK.DE - Merck KGaA | HOLD | 0 @ EUR 133.431 | EUR 0 | The current share valuation price of MRK.DE based on adjusted close was EUR 133.431. The average price that MRK.DE shares were previous bought at was EUR 130.447. The current market price is 2.3% higher than average price they were purchased at. The value of the holding in MRK.DE has increased by EUR 8,818 compared to the previous valuation of Merck KGaA however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| MTD - Mettler-Toledo International Inc | HOLD | 0 @ USD 1506.02 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1506.02. The average price that MTD shares were previous bought at was USD 1463.69. The current market price is 2.9% higher than average price they were purchased at. The value of the holding in MTD has increased by USD 82,524 compared to the previous valuation of Mettler-Toledo International Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| MTD - AMUNDI EUR GOV 710 | HOLD | 0 @ USD 1506.02 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1506.02. The average price that MTD shares were previous bought at was USD 1463.69. The current market price is 2.9% higher than average price they were purchased at. The value of the holding in MTD has increased by USD 82,524 compared to the previous valuation of AMUNDI EUR GOV 710 however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 143.53 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 143.53. The average price that NBIX shares were previous bought at was USD 140.213. The current market price is 2.4% higher than average price they were purchased at. The value of the holding in NBIX has increased by USD 4,259 compared to the previous valuation of Neurocrine Biosciences Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| NOVN.SW - | HOLD | 0 @ CHF 129.455 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 129.455. The average price that NOVN.SW shares were previous bought at was CHF 123.74. The current market price is 4.6% higher than average price they were purchased at. The value of the holding in NOVN.SW has increased by CHF 471,929 compared to the previous valuation of however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| NOVO-B.CO - Novo Nordisk A/S | HOLD | 0 @ DKK 46.4418 | DKK 0 | The current share valuation price of NOVO-B.CO based on adjusted close was DKK 46.4418. The average price that NOVO-B.CO shares were previous bought at was DKK 55.9384. The current market price is -17.0% lower than average price they were purchased at. The value of the holding in NOVO-B.CO has increased by DKK 628,090 compared to the previous valuation of Novo Nordisk A/S however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| NTRA - Natera Inc | HOLD | 0 @ USD 236.49 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 236.49. The average price that NTRA shares were previous bought at was USD 173.306. The current market price is 36.5% higher than average price they were purchased at. The value of the holding in NTRA has fallen by USD 6,476 compared to the previous valuation of Natera Inc |
| ORNBV.HE - Orion Oyj | HOLD | 0 @ EUR 69.664 | EUR 0 | The current share valuation price of ORNBV.HE based on adjusted close was EUR 69.664. The average price that ORNBV.HE shares were previous bought at was EUR 67.8405. The current market price is 2.7% higher than average price they were purchased at. The value of the holding in ORNBV.HE has increased by EUR 1,698 compared to the previous valuation of Orion Oyj however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| PFE - Pfizer Inc | HOLD | 0 @ USD 25.72 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 25.72. The average price that PFE shares were previous bought at was USD 24.7625. The current market price is 3.9% higher than average price they were purchased at. The value of the holding in PFE has increased by USD 125,994 compared to the previous valuation of Pfizer Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| PHIA.AS - Koninklijke Philips NV | HOLD | 0 @ EUR 27.7732 | EUR 0 | The current share valuation price of PHIA.AS based on adjusted close was EUR 27.7732. The average price that PHIA.AS shares were previous bought at was EUR 26.5139. The current market price is 4.7% higher than average price they were purchased at. The value of the holding in PHIA.AS has increased by EUR 5,732 compared to the previous valuation of Koninklijke Philips NV however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| PME.AX - | HOLD | 0 @ AUD 167.68 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 167.68. The average price that PME.AX shares were previous bought at was AUD 181.215. The current market price is -7.5% lower than average price they were purchased at. The value of the holding in PME.AX has fallen by AUD 369 compared to the previous valuation of |
| PODD - Insulet Corporation | HOLD | 0 @ USD 328.85 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 328.85. The average price that PODD shares were previous bought at was USD 333.441. The current market price is -1.4% lower than average price they were purchased at. The value of the holding in PODD has fallen by USD 25,736 compared to the previous valuation of Insulet Corporation |
| QIA.DE - QIAGEN NV | HOLD | 0 @ EUR 48.3197 | EUR 0 | The current share valuation price of QIA.DE based on adjusted close was EUR 48.3197. The average price that QIA.DE shares were previous bought at was EUR 45.759. The current market price is 5.6% higher than average price they were purchased at. The value of the holding in QIA.DE has increased by EUR 85,679 compared to the previous valuation of QIAGEN NV however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| REC.MI - Recordati Industria Chimica e Farmaceutica SpA | HOLD | 0 @ EUR 58.6218 | EUR 0 | The current share valuation price of REC.MI based on adjusted close was EUR 58.6218. The average price that REC.MI shares were previous bought at was EUR 58.4515. The current market price is 0.3% higher than average price they were purchased at. The value of the holding in REC.MI has increased by EUR 4,091 compared to the previous valuation of Recordati Industria Chimica e Farmaceutica SpA however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 787.32 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 787.32. The average price that REGN shares were previous bought at was USD 712.428. The current market price is 10.5% higher than average price they were purchased at. The value of the holding in REGN has increased by USD 174,105 compared to the previous valuation of Regeneron Pharmaceuticals Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| RMD - ResMed Inc | HOLD | 0 @ USD 255.8 | USD 0 | The current share valuation price of RMD based on adjusted close was USD 255.8. The average price that RMD shares were previous bought at was USD 256.073. The current market price is -0.1% lower than average price they were purchased at. The value of the holding in RMD has increased by USD 21,537 compared to the previous valuation of ResMed Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| RO.SW - | HOLD | 0 @ CHF 402.302 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 402.302. The average price that RO.SW shares were previous bought at was CHF 343.117. The current market price is 17.2% higher than average price they were purchased at. The value of the holding in RO.SW has increased by CHF 46,620 compared to the previous valuation of however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| ROG.SW - | HOLD | 0 @ CHF 388.191 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 388.191. The average price that ROG.SW shares were previous bought at was CHF 359.664. The current market price is 7.9% higher than average price they were purchased at. The value of the holding in ROG.SW has increased by CHF 146,941 compared to the previous valuation of however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 39.54 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 39.54. The average price that RPRX shares were previous bought at was USD 36.7765. The current market price is 7.5% higher than average price they were purchased at. The value of the holding in RPRX has fallen by USD 1,735 compared to the previous valuation of Royalty Pharma Plc |
| SAN.PA - Sanofi SA | HOLD | 0 @ EUR 99.8884 | EUR 0 | The current share valuation price of SAN.PA based on adjusted close was EUR 99.8884. The average price that SAN.PA shares were previous bought at was EUR 99.0472. The current market price is 0.8% higher than average price they were purchased at. The value of the holding in SAN.PA has increased by EUR 42,864 compared to the previous valuation of Sanofi SA however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| SDZ.SW - | HOLD | 0 @ CHF 69.2208 | CHF 0 | The current share valuation price of SDZ.SW based on adjusted close was CHF 69.2208. The average price that SDZ.SW shares were previous bought at was CHF 57.9682. The current market price is 19.4% higher than average price they were purchased at. The value of the holding in SDZ.SW has increased by CHF 3,519 compared to the previous valuation of however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| SHL.AX - | HOLD | 0 @ AUD 14.9506 | AUD 0 | The current share valuation price of SHL.AX based on adjusted close was AUD 14.9506. The average price that SHL.AX shares were previous bought at was AUD 15.0663. The current market price is -0.8% lower than average price they were purchased at. The value of the holding in SHL.AX has fallen by AUD 5,171 compared to the previous valuation of |
| SHL.DE - Siemens Healthineers AG | HOLD | 0 @ EUR 49.1753 | EUR 0 | The current share valuation price of SHL.DE based on adjusted close was EUR 49.1753. The average price that SHL.DE shares were previous bought at was EUR 53.4708. The current market price is -8.0% lower than average price they were purchased at. The value of the holding in SHL.DE has increased by EUR 3,841 compared to the previous valuation of Siemens Healthineers AG however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| SIG.AX - | HOLD | 0 @ AUD 1.87608 | AUD 0 | The current share valuation price of SIG.AX based on adjusted close was AUD 1.87608. The average price that SIG.AX shares were previous bought at was AUD 1.89691. The current market price is -1.1% lower than average price they were purchased at. The value of the holding in SIG.AX has fallen by AUD 10,625 compared to the previous valuation of |
| SN.L - Smith & Nephew PLC | HOLD | 0 @ GBP 16.6288 | GBP 0 | The current share valuation price of SN.L based on adjusted close was GBP 16.6288. The average price that SN.L shares were previous bought at was GBP 17.294. The current market price is -3.8% lower than average price they were purchased at. The value of the holding in SN.L has increased by GBP 3,072 compared to the previous valuation of Smith & Nephew PLC however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| SOBI.ST - | HOLD | 0 @ SEK 35.501 | SEK 0 | The current share valuation price of SOBI.ST based on adjusted close was SEK 35.501. The average price that SOBI.ST shares were previous bought at was SEK 32.9135. The current market price is 7.9% higher than average price they were purchased at. The value of the holding in SOBI.ST has increased by SEK 3,358 compared to the previous valuation of however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| SOLV - Solventum Corp. | HOLD | 0 @ USD 85.7699 | USD 0 | The current share valuation price of SOLV based on adjusted close was USD 85.7699. The average price that SOLV shares were previous bought at was USD 72.4742. The current market price is 18.3% higher than average price they were purchased at. The value of the holding in SOLV has increased by USD 9,204 compared to the previous valuation of Solventum Corp. however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| SOON.SW - | HOLD | 0 @ CHF 245.714 | CHF 0 | The current share valuation price of SOON.SW based on adjusted close was CHF 245.714. The average price that SOON.SW shares were previous bought at was CHF 275.476. The current market price is -10.8% lower than average price they were purchased at. The value of the holding in SOON.SW has increased by CHF 47,015 compared to the previous valuation of however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 281.2 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 281.2. The average price that SRT3.DE shares were previous bought at was EUR 254.653. The current market price is 10.4% higher than average price they were purchased at. The value of the holding in SRT3.DE has increased by EUR 94,356 compared to the previous valuation of Sartorius AG however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| STE - STERIS plc | HOLD | 0 @ USD 267.79 | USD 0 | The current share valuation price of STE based on adjusted close was USD 267.79. The average price that STE shares were previous bought at was USD 240.814. The current market price is 11.2% higher than average price they were purchased at. The value of the holding in STE has increased by USD 153,833 compared to the previous valuation of STERIS plc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| STMN.SW - | HOLD | 0 @ CHF 119.874 | CHF 0 | The current share valuation price of STMN.SW based on adjusted close was CHF 119.874. The average price that STMN.SW shares were previous bought at was CHF 121.695. The current market price is -1.5% lower than average price they were purchased at. The value of the holding in STMN.SW has fallen by CHF 15,348 compared to the previous valuation of |
| SYK - Stryker Corporation | HOLD | 0 @ USD 375.08 | USD 0 | The current share valuation price of SYK based on adjusted close was USD 375.08. The average price that SYK shares were previous bought at was USD 370.329. The current market price is 1.3% higher than average price they were purchased at. The value of the holding in SYK has increased by USD 76,171 compared to the previous valuation of Stryker Corporation however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| TEVA - Teva Pharma Industries Ltd ADR | HOLD | 0 @ USD 24.99 | USD 0 | The current share valuation price of TEVA based on adjusted close was USD 24.99. The average price that TEVA shares were previous bought at was USD 19.0228. The current market price is 31.4% higher than average price they were purchased at. The value of the holding in TEVA has increased by USD 5,525 compared to the previous valuation of Teva Pharma Industries Ltd ADR however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| TMO - Time Out Group plc | HOLD | 0 @ USD 597.78 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 597.78. The average price that TMO shares were previous bought at was USD 477.707. The current market price is 25.1% higher than average price they were purchased at. The value of the holding in TMO has increased by USD 252,327 compared to the previous valuation of Time Out Group plc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 272.991 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 272.991. The average price that UCB.BR shares were previous bought at was EUR 248.44. The current market price is 9.9% higher than average price they were purchased at. The value of the holding in UCB.BR has increased by EUR 16,595 compared to the previous valuation of UCB SA however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| UNH - UnitedHealth Group Incorporated | HOLD | 0 @ USD 326.28 | USD 0 | The current share valuation price of UNH based on adjusted close was USD 326.28. The average price that UNH shares were previous bought at was USD 320.557. The current market price is 1.8% higher than average price they were purchased at. The value of the holding in UNH has increased by USD 492,067 compared to the previous valuation of UnitedHealth Group Incorporated however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 485.77 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 485.77. The average price that UTHR shares were previous bought at was USD 419.012. The current market price is 15.9% higher than average price they were purchased at. The value of the holding in UTHR has increased by USD 7,790 compared to the previous valuation of United Therapeutics Corporation however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| VEEV - Veeva Systems Inc Class A | HOLD | 0 @ USD 239.95 | USD 0 | The current share valuation price of VEEV based on adjusted close was USD 239.95. The average price that VEEV shares were previous bought at was USD 284.797. The current market price is -15.7% lower than average price they were purchased at. The value of the holding in VEEV has increased by USD 115,611 compared to the previous valuation of Veeva Systems Inc Class A however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| VRTX - Vertex Pharmaceuticals Inc | HOLD | 0 @ USD 429.82 | USD 0 | The current share valuation price of VRTX based on adjusted close was USD 429.82. The average price that VRTX shares were previous bought at was USD 423.38. The current market price is 1.5% higher than average price they were purchased at. The value of the holding in VRTX has increased by USD 179,605 compared to the previous valuation of Vertex Pharmaceuticals Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| WAT - Waters Corporation | HOLD | 0 @ USD 412.54 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 412.54. The average price that WAT shares were previous bought at was USD 337.329. The current market price is 22.3% higher than average price they were purchased at. The value of the holding in WAT has increased by USD 203,242 compared to the previous valuation of Waters Corporation however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| WAT - MULETFWATIMETFP | HOLD | 0 @ USD 412.54 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 412.54. The average price that WAT shares were previous bought at was USD 337.329. The current market price is 22.3% higher than average price they were purchased at. The value of the holding in WAT has increased by USD 203,242 compared to the previous valuation of MULETFWATIMETFP however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| WST - West Pharmaceutical Services Inc | HOLD | 0 @ USD 280.84 | USD 0 | The current share valuation price of WST based on adjusted close was USD 280.84. The average price that WST shares were previous bought at was USD 264.273. The current market price is 6.3% higher than average price they were purchased at. The value of the holding in WST has increased by USD 10,391 compared to the previous valuation of West Pharmaceutical Services Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| ZBH - Zimmer Biomet Holdings Inc | HOLD | 0 @ USD 97.0699 | USD 0 | The current share valuation price of ZBH based on adjusted close was USD 97.0699. The average price that ZBH shares were previous bought at was USD 97.2797. The current market price is -0.2% lower than average price they were purchased at. The value of the holding in ZBH has increased by USD 15,077 compared to the previous valuation of Zimmer Biomet Holdings Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |
| ZTS - Zoetis Inc | HOLD | 0 @ USD 127.89 | USD 0 | The current share valuation price of ZTS based on adjusted close was USD 127.89. The average price that ZTS shares were previous bought at was USD 139.124. The current market price is -8.1% lower than average price they were purchased at. The value of the holding in ZTS has increased by USD 434,556 compared to the previous valuation of Zoetis Inc however if the holding was sold on 2025-11-25 this would crystalise an overall loss. |